Results 81 to 90 of about 1,058 (107)

Linking the relationship between drug-induced osteoporosis and the gut microbiota. [PDF]

Front Endocrinol (Lausanne)
Martiniakova M, Sarocka A, Penzes N, Mondockova V, Sevcikova A, Ciernikova S, Kovacova V, Biro R, Folwarczna J, Omelka R.   +9 more
europepmc   +1 more source

Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity. [PDF]

PNAS Nexus
Nakamura T, Okumura M, Takamune N, Hirotsu T, Sugiura M, Yasunaga J, Nakata H.   +6 more
europepmc   +1 more source

Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review. [PDF]

Infect Dis Ther
Boschloo WJ, van Welzen BJ.
europepmc   +1 more source

Clinical analysis of ten cases of HIV infection combined with acute leukemia. [PDF]

Open Med (Wars)
Fan S, Qian C, Tao P, Zhou Q, Lin S, Li K, Wang X, Min H.   +7 more
europepmc   +1 more source

Prolonged QT Interval in HIV-1 Infected Humanized Mice Treated Chronically with Dolutegravir/Tenofovir Disoproxil Fumarate/Emtricitabine. [PDF]

Int J Mol Sci
Namvaran A, Garcia JV, Ramasamy M, Nguyen K, Tavakkoli Ghazani F, Hackfort BT, Dash PK, Fisher RE, Edagwa B, Gorantla S, Bidasee KR.   +10 more
europepmc   +1 more source

Human Leukocyte Antigen (<i>HLA</i>) Signatures and Idiosyncratic Drug-Induced Liver Injury. [PDF]

Int J Mol Sci
Onaciu A, Grama A, Agoșton Ș, Mititelu A, Mariş B, Ştefănescu H, Pop TL.   +6 more
europepmc   +1 more source

Maternal Use of Integrase Strand Transfer Inhibitors During Pregnancy and Infant Neurodevelopment.

JAMA Netw Open
Williams PL, Boahene M, Mash LE, Chadwick EG, Huo Y, Spector SA, Oetting J, Garvie PA, Smith R.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Identification, Synthesis, and Strategy For Minimization of Potential Impurities Observed In Raltegravir Potassium Drug Substance

Organic Process Research and Development, 2012
Multiple sources of anticipated degradation and process impurities of raltegravir potassium drug substance observed during the laboratory optimization and later during its bulk synthesis are described in this article. The impurities were monitored by UPLC, and their structures are tentatively assigned on the basis of fragmentation patterns in LC–MS and
Mukund K Gurjar
exaly   +2 more sources

DoE-Based Solid Self-microemulsifying Drug Delivery System (S-SMEDDS) Approach for Improving the Dissolution Properties of Raltegravir Potassium

Journal of Pharmaceutical Innovation, 2022
Kiran Dudhat, M M Soniwala, Dudhat Kiran   +2 more
exaly   +2 more sources